Compass Pathways/$CMPS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Compass Pathways
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
- Ticker
- $CMPS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 156
- Headquarters
- London, United Kingdom
- Website
- compasspathways.com
Compass Pathways Metrics
BasicAdvanced
$1.2B
-
-$2.22
-
-
Price and volume
Market cap
$1.2B
52-week high
$15.87
52-week low
$4.88
Average daily volume
3.4M
Financial strength
Current ratio
1.496
Quick ratio
1.362
Long term debt to equity
0.36
Total debt to equity
0.383
Interest coverage (TTM)
-36.40%
Profitability
EBITDA (TTM)
-203.301
Effective tax rate (TTM)
1.30%
Management effectiveness
Return on assets (TTM)
-32.83%
Return on equity (TTM)
-296.45%
Valuation
Price to book
8.59
Price to tangible book (TTM)
8.59
Price to free cash flow (TTM)
-5.848
Free cash flow yield (TTM)
-17.10%
Free cash flow per share (TTM)
-1.472
Growth
Earnings per share change (TTM)
-18.71%
3-year earnings per share growth (CAGR)
-4.21%
What the Analysts think about Compass Pathways
Analyst ratings (Buy, Hold, Sell) for Compass Pathways stock.
Analyst projections of the future price of Compass Pathways stock.
Bulls say / Bears say
Two Phase 3 trials showed rapid benefit, with clinically meaningful improvement maintained through at least six months in a highly chronic treatment-resistant depression population. Replication across separate trials strengthens the case that COMP360 has real efficacy. (Compass Pathways, PharmaTimes)
The COMP005 extension reported benefit at one year after additional dosing, with 40–45% response rates and about 30% remission six weeks after a dose. If confirmed in practice, this could offer patients a treatment that does not require daily medication. (Compass Pathways)
Compass reported $433 million in cash at the end of June and expects it to fund operations into 2028. That should reduce the risk of needing another near-term financing before a potential launch. (Compass Pathways)
The one-year durability figures come from COMP005’s open-label extension, not a blinded comparison. That makes the long-term results less conclusive than the controlled trial data. (Compass Pathways)
A rival psilocybin treatment for major depression has also reached the FDA application stage, creating a potential competitor in the broader depression market. Usona’s application could receive an accelerated review, which may narrow Compass’s first-mover advantage. (Yahoo Finance)
COMP360 requires a supervised clinic session lasting about six hours, and specialist capacity may be difficult to scale. This could limit how quickly patients can access treatment even if the drug is approved. (MMM, Clinical Trial Vanguard)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
Compass Pathways Financial Performance
Revenues and expenses
Compass Pathways Earnings Performance
Company profitability
Upcoming events
No upcoming events
Compass Pathways News
AllArticlesVideos
Funds containing Compass Pathways
Fund name | Fund size | $CMPS weighting |
|---|---|---|
ARK Genomic Revolution€AAKG | $123M | 2.53% |
ARK Genomic Revolution£ARCG | $123M | 2.53% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.